May 2023 in “International Journal of Trichology” Tofacitinib effectively treated severe hair loss in a patient who didn't respond to other treatments.
Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
5 citations
,
August 2024 in “Frontiers in Immunology” Upadacitinib effectively treats psoriasiform eczema and some related conditions.
10 citations
,
July 2019 in “Indian Journal of Dermatology” Weekly azathioprine pulse is a better alternative to corticosteroids for treating alopecia areata due to fewer side effects.
75 citations
,
June 2005 in “Archives of Dermatology” Etanercept may not prevent alopecia areata from coming back.
February 2026 in “Oncology Reviews” Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.
6 citations
,
June 2008 in “Journal of the European Academy of Dermatology and Venereology” A man with Acrodermatitis continua did not get better with etanercept treatment, and his condition worsened, suggesting treatment effectiveness may vary by genetics and race.
May 2023 in “International Journal of Trichology” Tofacitinib may be an effective and safe treatment for hair loss in teenagers with alopecia areata.
13 citations
,
November 2021 in “Pediatric Dermatology” Tofacitinib taken by mouth helps treat hair loss in children.
9 citations
,
May 2019 in “Journal of dermatological treatment” Apremilast helps regrow hair in hard-to-treat alopecia areata.
July 2024 in “Journal of Investigative Dermatology”
52 citations
,
February 2006 in “Archives of Dermatology” Alefacept may effectively treat severe lichen planus, with patients showing significant improvement and no side effects.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
May 2015 in “Journal of The American Academy of Dermatology” Both treatments help with hair regrowth in alopecia areata, but azathioprine has milder side effects than betamethasone.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
97 citations
,
January 2006 in “Dermatology” imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.
1 citations
,
September 2025 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib is effective and safe for treating severe Alopecia Areata in adolescents.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
42 citations
,
January 1998 in “BioDrugs” Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.
September 2024 in “Journal of Cosmetic Dermatology” Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.
December 2025 in “PubMed” Upadacitinib and oral minoxidil improved Crohn's disease and hair regrowth in a patient.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
May 2024 in “Journal of cosmetic dermatology” Tofacitinib is an effective and safe treatment for alopecia areata.
December 2022 in “Zenodo (CERN European Organization for Nuclear Research)” Tofacitinib effectively treated severe alopecia areata in a 14-year-old girl.
February 2025 in “PubMed” CS12192 effectively treats alopecia areata with better safety than current options.
September 2024 in “Skin Appendage Disorders” Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.